Drug Survival, Safety, and Effectiveness of Secukinumab for up to 5 Years in Patients with Psoriasis and Psoriatic Arthritis: A Long-Term Real-Life Experience

塞库金单抗 医学 银屑病性关节炎 中止 银屑病 内科学 回顾性队列研究 多元分析 肥胖 队列 银屑病面积及严重程度指数 皮肤病科
作者
Luca Mastorino,Paolo Dapavo,Caterina Cariti,Sara Susca,Niccolò Siliquini,Michela Ortoncelli,Elena Stroppiana,Anna Verrone,Isotta Giunipero di Corteranzo,Francesco Leo,Pietro Quaglino,Simone Ribero
出处
期刊:Journal of Personalized Medicine [Multidisciplinary Digital Publishing Institute]
卷期号:14 (7): 718-718
标识
DOI:10.3390/jpm14070718
摘要

Introduction: the selective IL-17 inhibitor secukinumab has demonstrated efficacy and safety in the treatment of moderate–severe psoriasis in recent years. Objective: evaluate effectiveness and drug survival (DS) of secukinumab in patients with psoriasis for up to 5 years. Methods: This is a retrospective study on a monocentric cohort of patients with psoriasis on secukinumab evaluating the achievement of PASI100, PASI90, and PASI ≤ 3 and DS analysis up to 260 weeks. DS multivariate analysis was carried out considering sex, age, age of onset of the disease, obesity, cardiovascular comorbidities, diabetes, involvement of difficult-to-treat sites, psoriatic arthritis, treatment-naïve status, and mean baseline PASI. Results: At baseline, we evaluated 255 patients on secukinumab. PASI100 was reached by 41.7% and 70.6% of patients at weeks 16 and 260, respectively. PASI90 showed a similar trend with 46.5% of patients achieving it at week 16 and 88.2% at week 260. Non-obese patients showed a faster response than patients with obesity in achieving PASI100, PASI90, and PASI ≤ 3, with significant differences at 28 weeks [55% vs. 40% (p = 0.033), 64% vs. 49% (p = 0.038), and 76% vs. 62% (p = 0.036), respectively]. The estimated DS for secukinumab was 84.3% at 12 and 48% at 60 months. Obesity and smoking habits were associated with a higher risk of discontinuation in multivariate models (HR 1.6 CI 1.05–2.45, p = 0.028; HR 1.48 CI 1.01–2.17, p = 0.043, respectively). Conclusions: Secukinumab showed effectiveness for up to 5 years of treatment, with a high DS and achievement of PASI100, PASI90, and PASI < 3 at these time points. Only obesity reduced the response and maintenance of DS.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
多晶1完成签到,获得积分10
刚刚
1秒前
xingxingxing发布了新的文献求助10
1秒前
2秒前
5秒前
SciGPT应助q792309106采纳,获得10
5秒前
6秒前
上官若男应助卖萌的秋田采纳,获得10
6秒前
袁超发布了新的文献求助30
7秒前
张雯思发布了新的文献求助10
7秒前
JJ发布了新的文献求助10
7秒前
旧梦完成签到 ,获得积分10
8秒前
tramp应助xiamu采纳,获得20
9秒前
xingxingxing完成签到,获得积分10
10秒前
甜甜的悲发布了新的文献求助10
10秒前
量子星尘发布了新的文献求助10
10秒前
张钦奎发布了新的文献求助10
11秒前
11秒前
zhjg发布了新的文献求助10
12秒前
阿超完成签到,获得积分10
12秒前
FashionBoy应助凪凪采纳,获得10
14秒前
14秒前
wanci应助jinzhen采纳,获得10
15秒前
13发布了新的文献求助10
15秒前
小蘑菇应助甜甜的悲采纳,获得10
17秒前
GL发布了新的文献求助10
18秒前
袁超完成签到,获得积分10
18秒前
18秒前
忧郁盼夏发布了新的文献求助10
19秒前
19秒前
q792309106完成签到,获得积分10
20秒前
乖猫要努力应助郭小宝采纳,获得20
20秒前
q792309106发布了新的文献求助10
24秒前
24秒前
凪凪发布了新的文献求助10
24秒前
24秒前
情怀应助忧郁盼夏采纳,获得10
25秒前
wx完成签到,获得积分10
26秒前
27秒前
zyh完成签到 ,获得积分10
27秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989334
求助须知:如何正确求助?哪些是违规求助? 3531428
关于积分的说明 11253936
捐赠科研通 3270119
什么是DOI,文献DOI怎么找? 1804887
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809173